Last reviewed · How we verify
MiSaver
At a glance
| Generic name | MiSaver |
|---|---|
| Also known as | stem cells |
| Sponsor | Honya Medical Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II (PHASE2)
- MiSaver® Stem Cell Treatment for Acute Myocardial Infarction
- MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MiSaver CI brief — competitive landscape report
- MiSaver updates RSS · CI watch RSS
- Honya Medical Inc portfolio CI